Evidence map›Paper›PMID 31612307›Full record

ArticleInternational journal of hematology2020

Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan.

Masamitsu Yanada, Akiyoshi Takami, Shohei Mizuno, Jinichi Mori, Takaaki Chou, Kensuke Usuki, Hitoji Uchiyama, Itsuto Amano, Shiro Fujii, Toshihiro Miyamoto and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.Advances in experimental medicine and biology · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Masamitsu YanadaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. myanada@aichi-cc.jp.ORCID http://orcid.org/0000-0003-1602-9775
Akiyoshi TakamiAichi Medical University School of Medicine, Nagakute, Japan.
Shohei MizunoAichi Medical University School of Medicine, Nagakute, Japan.
Jinichi MoriJyoban Hospital of Tokiwa Foundation, Fukushima, Japan.
Takaaki ChouNiigata Cancer Center Hospital, Niigata, Japan.
Kensuke UsukiNTT Medical Center Tokyo, Tokyo, Japan.
Hitoji UchiyamaJapanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Itsuto AmanoNara Medical University Hospital, Kashihara, Japan.
Shiro FujiiTokushima University Hospital, Tokushima, Japan.
Toshihiro MiyamotoKyushu University Hospital, Fukuoka, Japan.
Takeshi SaitoThe Jikei University School of Medicine, Tokyo, Japan.
Tomohiko KamimuraHarasanshin Hospital, Fukuoka, Japan.
Tatsuo IchinoheResearch Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Takahiro FukudaNational Cancer Center Hospital, Tokyo, Japan.
Shinichiro OkamotoKeio University School of Medicine, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Shingo YanoThe Jikei University School of Medicine, Tokyo, Japan.

Funding

Aichi Cancer Research Foundation 2019-8Japan Agency for Medical Research and Development 18ek0510023h0002
6 · The paper itself

Abstract

Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine the implementation status and outcomes of autologous HCT for adults with AML in Japan, we analyzed data from 1,174 patients (including 446 with acute promyelocytic leukemia [APL]) who underwent autologous HCT between 1992 and 2016 consecutively reported to the Japanese nationwide transplantation registry. The annual number of transplantations peaked at 82 cases in 1997, and has recently remained at around 40 cases. The percentage of APL has increased sharply since 2004, and currently exceeds 70%. While most non-APL patients underwent autologous HCT during first complete remission (CR), transplantation during second CR has become mainstream for APL patients since the early 2000s. The 5-year survival, relapse, and non-relapse mortality rates were 55.3%, 42.1%, and 8.6% for non-APL patients, and 87.6%, 12.9%, and 3.4% for APL patients, respectively. Patients transplanted in the later period showed better survival than those transplanted in the earlier period, both for non-APL (P < 0.001) and APL (P = 0.036). These results clearly show the various changes in transplantation practice and post-transplant outcomes in Japan over the past 25 years.

Indexed as

AdolescentAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHematopoietic Stem Cell TransplantationHumansJapanLeukemia, Myeloid, AcuteLeukemia, Promyelocytic, AcuteMaleMiddle AgedRecurrenceRemission InductionRetrospective StudiesAcute myeloid leukemiaAcute promyelocytic leukemiaAutologous hematopoietic cell transplantation

Identifiers

PMID31612307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.